Evidence map›Paper›PMID 39027501›Full record

ArticleHeliyon2024

Bioflavonoid combination attenuates diabetes-induced nephropathy in rats via modulation of MMP-9/TIMP-1, TGF-β, and GLUT-4-associated pathways.

Ritu, Yifan Xiong, Hanuman Prasad Sharma, Ramesh K Goyal, Sonia Narwal, Ajay Berwal, Sourabh Jain, Meher Priya, Manisha Singh, Gaurav Agarwal and 3 more

Abstract read
In one paragraph

Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

RituDepartment of Pharmacology, Delhi Pharmaceutical Sciences & Research University, Mehrauli-Badarpur Road, Pushp Vihar Sector-3, New Delhi, 110017, India.
Yifan XiongDepartment of Pathology, Clinical Medical College and The First Affiliated Hospital of Chengdu Medical College, Chengdu, 610500, Sichuan, China.
Hanuman Prasad SharmaOcular Pharmacology and Pharmacy Division, Dr. Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, 110029, India.
Ramesh K GoyalDepartment of Pharmacology, Delhi Pharmaceutical Sciences & Research University, Mehrauli-Badarpur Road, Pushp Vihar Sector-3, New Delhi, 110017, India.
Sonia NarwalDepartment of Pharmacy, Panipat Institute of Engineering and Technology, Samalkha, Panipat, 132102, Haryana, India.
Ajay BerwalGeeta Institute of Pharmacy, Geeta University, Naultha, Panipat, 132145, Haryana, India.
Sourabh JainKewalshri Institute of Pharmacy, Khandwa Road, Indore, 452020, Madhya Pradesh, India.
Meher PriyaSchool of Medical and Allied Sciences, KR Mangalam University, Sohna Road, Gurugram, 122103, Haryana, India.
Manisha SinghSchool of Medical and Allied Sciences, KR Mangalam University, Sohna Road, Gurugram, 122103, Haryana, India.
Gaurav AgarwalDepartment of Pharmacy, Panipat Institute of Engineering and Technology, Samalkha, Panipat, 132102, Haryana, India.
Xiaoyan WangDepartment of Pathology, Clinical Medical College and The First Affiliated Hospital of Chengdu Medical College, Chengdu, 610500, Sichuan, China.
Bairong ShenJoint Laboratory of Artificial Intelligence for Critical Care Medicine, Department of Critical Care Medicine and Institutes for Systems Genetics, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, China.
Rajeev K SinglaJoint Laboratory of Artificial Intelligence for Critical Care Medicine, Department of Critical Care Medicine and Institutes for Systems Genetics, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Diabetic nephropathy represents a significant microvascular complication of diabetes, characterized by extracellular matrix accumulation, loss of cell-cell junctions, microalbuminuria, and diminished creatinine clearance. Despite its prevalence, therapeutic options dedicated to this condition are currently lacking. Natural products like bioflavonoids have garnered attention for their potential therapeutic benefits. The present study aimed to evaluate the efficacy of a bioflavonoid combination, including ginger extract, soy extract, and hesperetin, in a diabetic rat model. Methods: Diabetes was initiated in the rat pups via intraperitoneal injection of streptozotocin on the fifth postnatal day. After six weeks, rats exhibiting blood sugar levels exceeding 160 mg/dL were allocated into diabetic control and treatment groups, with eight animals each. A subset of rats received citrate buffer as a control. The treatment group received the bioflavonoid combination orally for twenty-four weeks. Various parameters, including glycemic levels, urinary parameters, antioxidant status, mRNA expression via Western blot, gel zymography, and immunohistochemistry, were assessed at the study's conclusion. Results: The bioflavonoid combination demonstrated significant reductions in hyperglycemia and various urinary parameters compared to controls. Notably, it modulated MMP-9/TIMP-1 expression, upregulated GLUT-4, and downregulated TGF-β. Additionally, the combination enhanced total antioxidant capacity, indicating potential antioxidative benefits. Conclusions: This study highlights the therapeutic potential of a bioflavonoid combination (ginger extract, soy extract, and hesperetin) in improving renal function in diabetic nephropathy. By modulating key factors such as MMP-9/TIMP-1, TGF-β, and GLUT-4, this combination presents a promising avenue for further exploration in managing diabetic nephropathy. These findings underscore the importance of natural products as potential therapeutic agents in addressing diabetic complications.

Indexed as

BioflavonoidsDiabetic nephropathyGLUT-4Medicinal plantsMMP-9Natural productsTGF-βTIMP-1

Identifiers

PMID39027501
PMCPMC11255568

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.